Neuroscience 2003 Abstract
| Presentation Number: | 100.3 |
|---|---|
| Abstract Title: | Expression of Bcl-x<sub>L</sub> after neonatal hypoxic ischemia in mice: effect of erythropoietin pretreatment. |
| Authors: |
Matsushita, H.*1
; Johnston, M. V.1
; Connor, K. S.1
; Wilson, M. A.1
1Dept. Neurosci. and Neurol., Kennedy Krieger Res. Inst. and Johns Hopkins Univ. Sch. of Med., Baltimore, MD |
| Primary Theme and Topics |
Neurological and Psychiatric Conditions - Ischemia -- Neuroprotection and tolerance |
| Secondary Theme and Topics | Development<br />- Trophic Factors and Developmental Cell Death<br />-- Cytokines and other factors: expression and biological effects |
| Session: |
100. Ischemia: Cell & Molecular Mechanisms I Poster |
| Presentation Time: | Saturday, November 8, 2003 3:00 PM-4:00 PM |
| Location: | Morial Convention Center - Hall F-I, Board # NN11 |
| Keywords: | Neuroprotection, apoptosis |
Systemic administration of erythropoietin (EPO) has neuroprotective effects in neonatal hypoxic ischemia (HI) (Matsushita et al., SFN Abstract, 2002). This neuroprotective effect may be related to Bcl-xL, an anti-apoptotic regulatory protein (Renzi et al., Brain Res Mol Brain Res 104:86, 2002, Wen TC et al., J Neurosci Res 67:795, 2002). To understand the mechanism of protective effect of EPO in neonatal period, we examined the effect of EPO on Bcl-xL mRNA expression in neonatal mice after HI. Animals were injected i.p. on postnatal day 7 with 5U/g EPO (n=11) or Vehicle (VEH, n=11). One hour later, a half of the animals in each treatment group were subject to HI. The right common carotid artery was ligated and animals recovered for 90 min. before hypoxic exposure (50 min, 10% O2). The remaining animals received Sham surgery. Brains were removed 3h after hypoxia, immediately frozen on dry ice and cut into 20µm sections. Bcl-xL mRNA level was examined in cortex with in situ hybridization. Bcl-xL mRNA expression was significantly reduced 3h after HI (p<0.001, ANOVA), however, the effect of surgery may differ in EPO and VEH-treated animals (surgery*EPO treatment, p=0.077). When considered separately, VEH-treated animals showed a significant reduction in Bcl-xL mRNA (p<0.001, t-test), and EPO-treated animals showed a trend toward reduced Bcl-xL mRNA (p=0.063, t-test). Thus, EPO may ameliorate the loss of Bcl-xL mRNA after HI, but this effect has only marginal significance at this time point. We have previously noted that there is a delay in the protective effect of EPO against neonatal HI. Further studies will be required to determine whether EPO significantly alters Bcl-xL mRNA at later time points.
Supported by: NIH NS28208.
Supported by: NIH NS28208.
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2003 Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2003. Online.
Copyright © 2003-2026 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
